China NMPA Drug Inspection - Diqing Development Zone Sanjiang Biological Development Co., Ltd. - Fritillaria cirrhosa
China NMPA drug inspection for Diqing Development Zone Sanjiang Biological Development Co., Ltd. published April 22, 2021. Drug: Fritillaria cirrhosa. On April 22, 2021, the Yunnan Provincial Drug Administration released its first announcement regarding substandard drug
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Diqing Development Zone Sanjiang Biological Development Co., Ltd. published April 22, 2021. Drug: Fritillaria cirrhosa. On April 22, 2021, the Yunnan Provincial Drug Administration released its first announcement regarding substandard drug
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox